Company news
Tenax Therapeutics, Inc. news in 2021
Tenax Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.
Tenax Therapeutics Reports Third Quarter 2021 Results and Provides Business Update
November 15, 2021
Tenax Therapeutics Announces Clearance of the Investigational New Drug Application for Imatinib in Pulmonary Arterial Hypertension (PAH)
October 5, 2021
Tenax Therapeutics Reports Second Quarter 2021 Results and Provides Business Update
August 16, 2021
Tenax Announces New Publication Highlighting Novel Levosimendan Mechanism of Action in Pulmonary Hypertension Patients with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)
August 11, 2021
Tenax Therapeutics Announces CEO Transition and $10 Million PIPE Offering Priced At-the-Market under Nasdaq Rules
July 6, 2021
Tenax Therapeutics Reports First Quarter 2021 Results and Provides Business Update
May 16, 2021
Tenax Announces Publication Titled “Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF: Results of the Randomized Placebo-Controlled HELP Trial ”
April 8, 2021
Tenax Therapeutics Announces Continuation of Board Refreshment Program as Three Long-Serving Directors Volunteer to Not Stand for Re-Election at the Upcoming 2021 Annual Meeting of Stockholders
April 6, 2021
Tenax Therapeutics Reports Fiscal Year 2020 Results and Provides Business Update
March 30, 2021
Tenax Therapeutics, Inc. Expands Board of Directors
March 1, 2021
Tenax Therapeutics, Inc. Announces Transformative Acquisition of PH Precision Med
January 18, 2021
Decks in 2021
- CVCT 2021
Conference · 24 slides · 2021